Drug Profile


Alternative Names: Simmitecan hydrochloride

Latest Information Update: 28 Dec 2016

Price : $50

At a glance

  • Originator ShangHai HaiHe Pharmaceutical
  • Class Alkaloids; Antineoplastics; Camptothecins; Esters; Small molecules
  • Mechanism of Action DNA topoisomerase I inhibitors; Hypoxia-inducible factor 1 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Solid tumours

Most Recent Events

  • 28 Dec 2016 Simmitecan is still in phase I trials for Solid tumours in China (NCT01832298)
  • 12 Aug 2016 ShangHai HaiHe Pharmaceutical plans a phase I study in Solid tumours (Monotherapy, Combination therapy) or Colorectal cancer (Combination therapy) in China (NCT02870036)
  • 01 Aug 2016 ShangHai HaiHe Pharmaceutical completes a phase I trial in Solid tumours (late-stage disease, second-line or greater therapy) in China (IV) (lNCT01832298)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top